196 related articles for article (PubMed ID: 24265292)
1. Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours.
Rose M; Gaisa NT; Antony P; Fiedler D; Heidenreich A; Otto W; Denzinger S; Bertz S; Hartmann A; Karl A; Knüchel R; Dahl E
Carcinogenesis; 2014 Mar; 35(3):727-36. PubMed ID: 24265292
[TBL] [Abstract][Full Text] [Related]
2. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
[TBL] [Abstract][Full Text] [Related]
3. [Novel prognostic marker in invasive breast cancer. ITIH5 expression is abrogated by aberrant promoter methylation].
Veeck J; Breuer E; Rose M; Chorovicer M; Naami A; Bektas N; Alkaya S; von Serényi S; Horn F; Hartmann A; Knüchel R; Dahl E
Pathologe; 2008 Nov; 29 Suppl 2():338-46. PubMed ID: 18810445
[TBL] [Abstract][Full Text] [Related]
4. ITIH5 mediates epigenetic reprogramming of breast cancer cells.
Rose M; Kloten V; Noetzel E; Gola L; Ehling J; Heide T; Meurer SK; Gaiko-Shcherbak A; Sechi AS; Huth S; Weiskirchen R; Klaas O; Antonopoulos W; Lin Q; Wagner W; Veeck J; Gremse F; Steitz J; Knüchel R; Dahl E
Mol Cancer; 2017 Feb; 16(1):44. PubMed ID: 28231808
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype.
Kloten V; Rose M; Kaspar S; von Stillfried S; Knüchel R; Dahl E
Epigenetics; 2014 Sep; 9(9):1290-301. PubMed ID: 25093535
[TBL] [Abstract][Full Text] [Related]
6. Gene expression analysis combined with functional genomics approach identifies ITIH5 as tumor suppressor gene in cervical carcinogenesis.
Dittmann J; Ziegfeld A; Jansen L; Gajda M; Kloten V; Dahl E; Runnebaum IB; Dürst M; Backsch C
Mol Carcinog; 2017 Jun; 56(6):1578-1589. PubMed ID: 28059468
[TBL] [Abstract][Full Text] [Related]
7. OASIS/CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro.
Rose M; Schubert C; Dierichs L; Gaisa NT; Heer M; Heidenreich A; Knüchel R; Dahl E
Epigenetics; 2014 Dec; 9(12):1626-40. PubMed ID: 25625847
[TBL] [Abstract][Full Text] [Related]
8. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.
Noetzel E; Rose M; Sevinc E; Hilgers RD; Hartmann A; Naami A; Knüchel R; Dahl E
Oncogene; 2010 Aug; 29(34):4814-25. PubMed ID: 20543860
[TBL] [Abstract][Full Text] [Related]
9. Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.
Dötsch MM; Kloten V; Schlensog M; Heide T; Braunschweig T; Veeck J; Petersen I; Knüchel R; Dahl E
Epigenetics; 2015; 10(10):903-12. PubMed ID: 26252352
[TBL] [Abstract][Full Text] [Related]
10. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.
Duarte-Pereira S; Paiva F; Costa VL; Ramalho-Carvalho J; Savva-Bordalo J; Rodrigues A; Ribeiro FR; Silva VM; Oliveira J; Henrique R; Jerónimo C
Eur J Cancer; 2011 May; 47(7):1106-14. PubMed ID: 21273058
[TBL] [Abstract][Full Text] [Related]
12. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
13. ITIH5 induces a shift in TGF-β superfamily signaling involving Endoglin and reduces risk for breast cancer metastasis and tumor death.
Rose M; Meurer SK; Kloten V; Weiskirchen R; Denecke B; Antonopoulos W; Deckert M; Knüchel R; Dahl E
Mol Carcinog; 2018 Feb; 57(2):167-181. PubMed ID: 28940371
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of ST6GAL1 in human bladder cancer.
Antony P; Rose M; Heidenreich A; Knüchel R; Gaisa NT; Dahl E
BMC Cancer; 2014 Dec; 14():901. PubMed ID: 25465919
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic biomarkers in urothelial bladder cancer.
Kim WJ; Kim YJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
[TBL] [Abstract][Full Text] [Related]
17. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
[TBL] [Abstract][Full Text] [Related]
18. DBC2 gene is silenced by promoter methylation in bladder cancer.
Shi Y; Chen JY; Yang J; Li B; Chen ZH; Xiao CG
Urol Oncol; 2008; 26(5):465-9. PubMed ID: 18640857
[TBL] [Abstract][Full Text] [Related]
19. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.
Chen PC; Yu HJ; Chang YH; Pan CC
J Clin Pathol; 2013 Feb; 66(2):113-9. PubMed ID: 23087329
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
